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Abstract
Clinician attitudes towards multiplexed genomic testing may be vital to the success of translational 
programs. We surveyed clinicians at an academic medical center about their views on a large 
pharmacogenomics implementation, the PREDICT (Pharmacogenomic Resource for Enhanced 
Decisions in Care & Treatment) program. Participants were asked about test ordering, major 
factors influencing use of results, expectations of efficacy, and responsibility for applying results 
to patient care. Virtually all respondents (99%) agreed that pharmacogenomics variants influence 
patients’ response to drug therapy. The majority (92%) favored immediate, active notification 
when a clinically significant drug-genome interaction was present. However, clinicians were 
divided on which providers were responsible for acting on a result when a prescription change was 
indicated and whether patients should be directly notified of a significant result. We concluded 
genotype results were valued for tailoring prescriptions, but clinicians do not agree on how to 
appropriately assign clinical responsibility for actionable results from a multiplexed panel.
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The introduction of pharmacogenomics into clinical settings is accelerating as academic 
medical centers and integrated health systems have implemented pharmacogenomic testing, 
encouraged routine use within prescribing, and placed results within electronic health 
records (EHR).1–7 Many programs have adopted multiplexed, panel testing - in which 
multiple variants are tested simultaneously to inform prescribing- to leverage economies of 
scale and the potential for reuse of panel data over time.7–9 However, multiplexed testing 
may present challenges as clinicians may be expected to apply pharmacogenomic test results 
that were ordered in an unrelated clinical context and to consider genomic risks that are not 
relevant to their usual scope of practice.
Concerns about the ability of front line clinicians to manage genomic data are highlighted by 
surveys and qualitative studies of likely users.10–14 Nationally, fewer than one in eight 
primary care physicians has ordered a pharmacogenomic test or felt adequately informed to 
use the result. Within implementation programs, significant new educational efforts and 
clinical decision support strategies are designed to bridge this knowledge gap.1,3 However, 
little has been reported on the views of clinicians working in these new programs.
Education and implementation assistance from medical geneticists and knowledgeable 
pharmacists has been anticipated from the onset of genomic medicine.15 Even with the 
assistance of sophisticated EHR tools, clinicians’ understanding of pharmacogenomics and 
active engagement with pharmacogenomic testing is critical for test adoption and utilization. 
We report the outcomes of a survey administered to clinicians participating in a large 
pharmacogenomics program within an academic medical center. Those solicited had either 
requested or received results from a multiplexed pharmacogenomics panel performed for 
primary care and cardiovascular patient populations between 2010–2013.1 The present 
analysis focuses on clinicians’ perceptions of clinical utility, preparedness to effectively use 
pharmacogenomic test results, and questions of responsibility for disclosure and clinical use 
of multiplexed results over the course of patients’ care.
Materials and Methods
Pharmacogenomics Implementation
Clinicians solicited for this study participated in an institutional pharmacogenomics program 
launched in 2010. The program was designed to pre-emptively genotype patients, store 
actionable results as determined by the local pharmacy and therapeutics (P&T) committee, 
and provide program interpretations and recommendations at the point of care. During the 
initial implementation, program leaders gave educational seminars, distributed informational 
brochures, and conducted direct communications with clinicians through email and in-
person meetings. The program created a web site summarizing the evidence for applying the 
tested variants to clinical care and linked pharmacogenomic results to the relevant page.1 
Inpatient and outpatient clinical decision support provided guidance at the point of 
medication prescribing for five drugs, including clopidogrel and warfarin, during the survey 
period.2 A pharmacist-led active surveillance program focused on CYP2C19 and clopidogrel 
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ensured key results were delivered to cardiology attending physicians following coronary 
stent placement.16 As part of program development, members of the patient population 
served by the institution gave feedback and guidance to program development as part of 
focus groups. Pharmacogenomic testing was performed under the terms of treatment consent 
similar to other laboratory testing within a health care environment.
Development of survey
Investigators conducting pharmacogenomics research developed the survey. Questions were 
based on a prior publication by Stanek, et al.,10 and contributions from authors. Two 
clinicians piloted the survey for clarity and completeness of the potential responses. The 
survey was designed to address the following domains: perception of clinical utility, 
preparedness to receive results, and assignment of clinical responsibility for communicating 
results and adjusting medications as warranted over the course of the patient’s care.
Sampling method
The survey was distributed by email between November 2012 and March 2013 to all 
clinicians within cardiology, primary care, and endocrinology who met the following 
criteria: 1) had ordered a panel-based test via the pharmacogenomics implementation or 
cared for a patient with a pharmacogenomic result in the previous one year and 2) held a 
position as an attending physician, specialty fellow physician, or nurse practitioner position 
with active prescribing privileges.
Collection of survey responses
Survey items were entered into REDCap, which features a secure environment for building 
and managing online surveys for research.17 A unique access code was created for each 
solicited subject, allowing the responses to be collected anonymously. After the initial email 
solicitation, non-responders were solicited with two additional emails. A modest incentive 
was provided for completing the survey. The Vanderbilt Institutional Research Board 
approved the study.
Data Analysis
Responses were included in the analysis if the majority of coded questions were answered 
including the key questions related to responsibility for results. Responses were tabulated as 
numeric counts and frequencies. Respondents were stratified by cardiology and non-
cardiology specialty for the analysis related to questions about clinical responsibility for 
acting on pharmacogenomic results where a prescription change was indicated. All analyses 
were conducted in R version 3.0.1 (Vienna, Austria).
Results
Of 156 surveys distributed, 80 (52%) were returned with a complete response and 4 (3%) 
were returned incomplete. Respondents were evenly split between clinicians practicing 
cardiology (51%) and those practicing primary care or endocrinology (49%). Survey 
respondents were predominantly young with less than 15 years of practice (71%) and female 
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(63%). Approximately half were attending faculty while the remainder consisted of nurse 
practitioners and fellows (Table 1).
Preparedness to order pharmacogenomic testing
As expected based on study inclusion criteria, two-thirds (63%) had ordered or 
recommended a pharmacogenomic test in the prior six months. A high proportion of 
respondents (95%) were familiar with the institutional pharmacogenomics program. Nearly 
all (94%) prescribed at least one of the three drugs targeted by the program at the time of 
survey: simvastatin, clopidogrel, and warfarin. When deciding whether to order a 
pharmacogenomic test, the most important considerations reported were strength of 
evidence for the drug-gene interaction and patients’ out of pocket costs for testing (Figure 
1).
Perception of clinical utility
All but one respondent (99%) agreed that pharmacogenomic variants influence patients’ 
response to drug therapy. The majority agreed or strongly agreed with the clinical utility of 
CYP2C19 variants to tailor antiplatelet therapy following percutaneous coronary 
interventions (80%) and VKORC1 and CYP2C9 variants to tailor initial warfarin dosing 
(86%). The majority also agreed or strongly agreed that the variants affected patient 
outcomes, such as stent thrombosis and warfarin-related bleeding (Figure 2).
We asked participants to indicate which sources of information were of major, minor, or no 
importance to their perception of pharmacogenomic clinical utility. As indicated in Figure 3, 
respondents ranked published literature including systematic reviews and specialty society 
guidelines higher than guidance from the implementing institution, from a third party 
laboratory, or from Food and Drug Administration (FDA) approved medication labels.
Preparedness to receive results
A minority of the respondents (19%) reported no prior instruction in pharmacogenomics; the 
remainder had completed undergraduate courses (11%), professional school instruction 
(31%), postgraduate coursework (23%), continuing medical education seminars (52%), or 
self-instruction by reading peer reviewed literature (51%). Overall, 70% of respondents felt 
they had adequate educational resources in the clinic to support clinical decision-making 
related to pharmacogenomics, a proportion that did not significantly differ between 
cardiology and non-cardiology providers (p=0.63). Many who did not feel adequate 
resources were available submitted free text responses requesting more point-of-care 
guidance with links to primary sources in the literature. Additionally, providers requested 
supplemental information geared towards patients to reduce the time required to educate 
patients about genomic variants and the rationale for tailoring therapy.
Responsibility for results
Survey subjects were asked to respond to two clinical scenarios applying pharmacogenomic 
results to clinical decision-making and to select which providers were responsible for 
clinical action (Table 2). The first scenario was modeled after the most common drug-
genome interaction encountered at the time of the survey: prescribing clopidogrel in the 
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setting of an intermediate or poor metabolism phenotype for CYP2C19. In the second 
scenario, new pharmacogenomic information pertinent to warfarin dosing became available 
months after the patient was initially tested. In both cases, respondents were asked to 
identify who should be notified and who should be responsible for acting on this result. 
Respondents could choose multiple selections.
No agreement emerged about which group of providers should be notified or who should 
take responsibility for clinical action when necessary. In the first scenario of an actionable 
result for clopidogrel and CYP2C19, most agreed that multiple providers should be notified; 
however, only 44%–49% agreed that the patient should also be directly notified (Table 1). 
The clinician most commonly selected by cardiologists for direct notification was the 
specialist treating the medical condition (90%) while non-cardiologists chose the provider 
who prescribed the drug affected by the result (95%). There was less agreement about which 
provider is responsible for acting on the result, but both groups most commonly chose the 
specialist treating the medical condition affected by the result (74–80%). Nearly all (92% in 
each group) wanted active notification as soon as the results were reported.
The second scenario also gave an actionable result, but this pharmacogenomic result for 
guiding initial warfarin dosing became available six months following the original testing. 
Again, about half of the respondents (46–54%) felt that the patient should be notified 
directly and the majority of respondents indicated that multiple clinicians should also be 
notified. While cardiologists most commonly selected the provider who would prescribe 
warfarin (85%), non-cardiologists selected both this option (77%) and the primary care 
provider (77%). Both cardiologists and non-cardiologists most commonly assigned 
responsibility for follow-up for this delayed result to the implementation program staff, to 
the provider who initially ordered the pharmacogenomic panel, or to both.
Discussion
Within an institutionally supported pharmacogenomics implementation program, clinicians 
expressed support for the concept that pharmacogenomic variants affect drug responses and 
more than 80% agreed that common drug-genome interactions for clopidogrel and warfarin 
reported by the program had clinical utility. The majority reported prior instruction in 
pharmacogenomics and felt adequately supported to use the results in clinical practice. 
National guidelines and published literature were favored as sources of guidance over local 
initiatives such as computerized prompts and institutional recommendations.
Several of these findings are distinct from those obtained from prior studies of physicians 
who practiced outside an implementation program. In one national survey, physicians 
reported near universal acceptance of the concept of pharmacogenomics, but had 
infrequently been educated on the topic and felt unprepared for test ordering and using the 
results.10 A second regional survey of primary care physicians and family practitioners 
yielded similar results.11 The differences highlight the importance of implementation 
programs to prepare end-users for ordering and interpreting pharmacogenomic results.
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Our survey identified a lack of agreement regarding which clinician should be responsible 
for results with either immediate or potentially persistent value. Respondents assigned 
responsibility for long-term follow-up of genomic test results to an inconsistent array of 
providers, ranging from specialists to primary care providers to the administrative staff of 
the implementation program. In retrospect, this was not surprising since pharmacogenomics 
results can apply to a wide variety of clinical scenarios and survey respondents may not have 
felt comfortable with genetic information not directly related to their specialty. Nonetheless, 
this lack of agreement about who should act on pharmacogenomic results raises the risk that 
some patients may fall through the cracks. As a result, more work is needed to create 
systems for return of results that clearly assign responsibility for clinical action related to 
genomic variants.
Our study has several limitations. Subjects were selected within a tertiary care academic 
medical center program and survey responses may not be representative of the general 
practitioner population. Given the rapid changes in the evidence base for drug-genome 
interactions, survey responses related to specific clinical scenarios are expected to change 
over time. For example, the survey was performed prior to the publication of several large-
scale studies of pharmacogenomic-guided dosing for warfarin,18,19 and thus, the physician 
responses presented here may not be fully indicative of current attitudes and practice related 
to that particular drug-gene interaction. Finally, clinicians may be influenced by a broader 
array of information sources than those indicated in the survey, and attitudes and preferences 
expressed by survey respondents may not always correspond with information-seeking 
behavior in the clinic.20
The growth of multiplexed pharmacogenomic testing is anticipated to occur both within and 
outside of the context of institutional implementation programs. Physicians operating within 
an implementation program report greater prior knowledge and educational support to order 
and use pharmacogenomic results than previously published results from a national sample. 
However, even in the context of a single health system, dilemmas persist related to assigning 
responsibility for pharmacogenomic results and require new strategies to ensure that patients 
receive the benefits of high-quality genome-informed care.
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Figure 1. Influential factors reported by clinicians when deciding whether to order a 
pharmacogenomics panel test
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Figure 2. Attitudes towards clinical utility of genomic variants to tailor prescriptions
Likert scale responses indicating strongly agree and strongly disagree are collapsed into 
agree and disagree categories.
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Figure 3. Influential factors reported by clinicians when deciding to use pharmacogenomic 
variants to tailor therapy
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   20–30 0 (0) 0 (0) 0 (0)
   31–40 22 (54) 20 (51) 42 (52)
   41–50 7 (17) 12 (31) 19 (24)
   51–60 7 (17) 4 (10) 11 (14)
   61–70 3 (7) 2 (5) 5 (6)
   >71 2 (5) 1 (3) 3 (4)
Gender
   Male 11 (27) 19 (49) 30 (38)
   Female 30 (73) 20 (51) 50 (63)
Years of clinical practice
   <5 9 (22) 6 (15) 15 (19)
   5–10 13 (32) 14 (36) 27 (34)
   11–15 5 (12) 10 (26) 15 (19)
   16–20 3 (7) 5 (13) 8 (10)
   21–25 0 (0) 0 (0) 0 (0)
   >25 11 (27) 4 (10) 15 (19)
Practice Specialty
   Internal Medicine: Primary Care Physician 0 (0) 21 (54) 21(26)
   Internal Medicine: Hospitalist 0 (0) 0 (0) 0 (0)
   Medical Specialty: Interventional Cardiology 11 (27) 0 (0) 11(14)
   Medical Specialty: General Cardiology 30 (73) 0 (0) 30(38)
   Medical Specialty: Endocrinologist 0 (0) 7 (18) 7(9)
   Pediatrics 0 (0) 1 (3) 1(1)
   Other 0 (0) 10 (26) 10(13)
Position
   Physician 19 (46) 32 (82) 51 (64)
   Fellow 12 (29) 1 (3) 13 (16)
   Resident physician 0 (0) 0 (0) 0 (0)
   Nurse practitioner 8 (20) 6 (15) 14 (18)
   Physician assistant 0 (0) 0 (0) 0 (0)
   Other 2 (5) 0 (0) 2 (2.5)
Number of half-day outpatient sessions per week
   0–2 30 (73) 18 (46) 48 (60)
   3–4 8 (20) 6 (15) 14 (18)
   5–6 0 (0) 4 1(0) 4 (5)




















   7–8 0 (0) 9 (23) 9 (11)
   9–10 3 (7) 2 (5) 5 (6)
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Table 2
Clinician attitudes regarding notification and responsibility for acting on a pharmacogenomics result
Clinical scenario: A 65 year old patient with diabetes and hypertension experiences angina with brisk walking. Nuclear stress testing reveals 
evidence of cardiac ischemia. Upon referral to an interventional cardiologist, he is scheduled for elective angiography the following day and 
receives pharmacogenomic testing. He is prescribed aspirin and clopidogrel after successful placement of a drug-eluting stent and is discharged. 
One week later, the result of the pharmacogenomic test is returned and indicates that the patient is homozygous for the CYP2C19 *2 variant and 






In addition to including the results in the electronic medical record 
(EMR), who should be individually notified of the new 
pharmacogenomics result? (check all that apply)
Not necessary to notify any provider directly 0 (0) 0 (0)
Primary care provider 22 (54) 27 (69)
Specialist treating medical condition affected by test result 37 (90) 35 (90)
Provider who ordered pharmacogenomic test 31 (76) 27 (69)
Provider who prescribed drug therapy affected by test 33 (80) 37 (95)
Patient should be notified directly 18(44) 19 (49)
Which of the patient’s providers is responsible for acting on a 
pharmacogenomic result if a prescription change is indicated? 
(check all that apply)
Primary care provider 3(7) 7 (18)
Specialist treating medical condition affected by test result 33 (80) 29 (74)
Provider who ordered pharmacogenomic test 23(56) 20 (51)
Provider who previously prescribed drug therapy affected by test 20 (49) 23 (59)
When should providers be actively notified (e.g. with a reminder or 
prompt) if a prescription change based on the pharmacogenomic 
result is indicated?
As soon as results are available in the EMR 37 (92) 36 (92)
During the next appointment at Vanderbilt 1 (2) 1 (3)
Only when selecting antiplatelet medication using e-script 2 (5) 1 (3)
No reminder or prompt necessary 0 (0) 1 (3)
Continued scenario: Six months following the patient’s stent placement, the program begins reporting genetic results to guide warfarin 
therapy. Based on genetic and clinical variables, the patient is expected to have a stable therapeutic INR1 on a low dose of warfarin (<21mg/
week) and increased risk of bleeding on standard or high doses of warfarin. Since his stent, the patient has resumed care with his primary care 
provider and cardiologist in his home town.







Vanderbilt provider who has seen the patient most recently 11 (27) 8 (21)
Primary care provider 27 (66) 30 (77)
Specialist treating medical condition affected by test result 31 (76) 28 (72)
Provider who ordered the pharmacogenomic test 24 (59) 22 (56)
Provider who will prescribe drug therapy affected by test 35 (85) 30 (77)
Patient should be notified directly 19 (46) 21 (54)
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Who, within Vanderbilt, should take responsibility for following up 
with the patient or outside providers? (check all that apply)
Vanderbilt provider who has seen the patient most recently 9 (22) 4 (10)
Vanderbilt provider who ordered the pharmacogenomic test 21 (51) 24 (62)
PREDICT2 staff should contact the providers 28 (68) 28 (72)
PREDICT staff should contact the patient directly 11 (27) 12 (31)
What are your preferred methods of receiving notification of a 
pharmacogenomic result that may require you to take clinical action?
Standard laboratory reporting in EMR3 15 (37) 19 (49)
Phone call from PREDICT staff 4 (10) 3 (8)
Electronic clinical message from PREDICT staff 33 (80) 27 (69)
Clinical decision support via e-prescribing and computerized physician 
order entry
15 (37) 16 (41)
Message to nursing staff or pharmacy directly 1 (2) 0 (0)
1
INR = International Normalized Ratio
2
PREDICT is the name of the institutional pharmacogenomics program
3
EMR = Electronic Medical Records
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